ArticleBMC infectious diseases2025
Molecular characteristics of hepatitis B virus among students and pregnant women in Chad.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic, preventive, and pathogenetic advances in viral hepatitis.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B virus (HBV) infection remains a global public health problem claiming about 1, 1 million lives among the several hundred million people infected with the virus globally. However, low- and middle-income countries including those in sub-Saharan Africa carry the highest burden but limited knowledge of the pathogen. This calls for studies to characterise the circulating genotypes of the virus in Sub-Saharan Africa. This study, sought to determine the molecular characteristics of HBV circulating among pregnant women and students in Chad.
methodsVenous blood samples were collected from pregnant women and students in the capital of Chad between April and August 2021. Whole blood samples were spun at 2500xg at 4 °C for 10 min to separate the cellular parts from the sera. The resulting sera were tested for Hepatitis B surface antigen (HBsAg) using enzyme-linked immunosorbent assay (ELISA). HBsAg positivity was confirmed using the Abbott Architect i1000SR analyser. HBV-DNA viral load detection was performed for HBsAg positive sera. HBV-DNA viral load was determined in HBsAg positive sera samples. The S gene was amplified by nested PCR followed by visualisation of the resulting amplicons under UV transillumination after gel electrophoresis. The amplicons were sequenced using the Sanger technique and subjected to phylogenetic and mutational analyses.
resultsA total of 101 HBsAg-positive participants (recruited among students and pregnant women) were included in the study. The mean age was 25 years and 51.49% were males. Viral load was measured in 53 participants, among whom 27 (50.94%) had a viremia higher than 2000 IU/ml. The constructed phylogeny using 31 samples based of the HBV S gene showed that all strains belonged to the E genotype and evolutionary related to HBV from Cameroon, Central African Republic, Burkina Faso, Sudan and Ghana. The comparative mutational analysis identified low intragroup genetic diversity (0.004%) between Chadian strains with only two loci (codon positions 126 and 141) having nonsynonymous mutations including (Y126H, Y126N, Y126C, L140I, Y141S, Y141R, Y141H, Y141F).
conclusionsThe study shows the presence and circulation of HBV genotype E in Chad. The Chadian strains, compared to other genotype E strains from surrounding countries have very low genetic variability. The presence of immune escape mutations in the HBV S gene could be responsible for escape vaccine strains and thus reduce the efficacy of vaccination. Additionally, the presence of the transmembrane domain in the HBV S gene could alter the antigenicity of HBsAg, contributing to screening failure by standard tests (HBsAg negative despite active infection) or reduce the efficacy of drugs that target HBsAg. These results highlight the need to evaluate hepatitis B vaccination coverage and efficiency in Chad.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.